3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
AMASS Brands said its Chief Financial Officer, Zachary Ament, will resign effective November 16, 2026, and that Geoffrey McFarlane will serve as Interim Chief Financial Officer from November 17, 2026. The filing also reports a revised Series C Preferred Stock certificate that lowers the conversion price floor and a termination of a warrant held by Streeterville Capital, LLC.
CFO Zachary Ament resigned, effective November 16, 2026; the company said the resignation was not due to any disagreement on operations, policies, or financial disclosures.
Geoffrey McFarlane, age 43, was appointed Interim CFO effective November 17, 2026, while the board searches for a permanent CFO.
On October 22, 2026, the Series C Preferred Stock floor price was reduced from $4.00 to $1.00 per share.
The warrant to buy up to 3,500,000 common shares held by Streeterville Capital, LLC was terminated and cancelled, with no payment due from the company.
Traws Pharma entered a Common Stock Purchase Agreement with Roth Principal Investments, allowing the company to sell up to $50,000,000 of newly issued common stock over time at its own discretion. The company is under no obligation to sell any shares, and sales can begin only after a registration statement covering the resale of those shares is declared effective by the SEC.
Total commitment of up to $50,000,000 in newly issued common stock, at the company's option
Purchase price set at 94.0% of volume weighted average price, a fixed 6.0% discount, for market open, intraday, pre-market and post-market purchases
Sales require the closing price to be at least $0.10 (Threshold Price) and an effective registration statement; the period runs 36 months from the Commencement Date
Agreement dated October 23, 2026, with a related Registration Rights Agreement
Melar Acquisition Corp. I shareholders approved the business combination with Everli Global Inc. and related proposals at an extraordinary general meeting on October 22, 2026, with no votes against any proposal reported as zero abstentions. Holders of 3,852,564 Class A shares redeemed for a pro rata share of the trust account, leaving approximately $0.8 million in the trust after redemptions, and Melar expects the combination to close promptly once remaining conditions are met.
Business Combination Proposal: 9,425,113 votes for and 23,978 against, with 0 abstentions
Redemptions: 3,852,564 Melar Class A Ordinary Shares redeemed; approximately $0.8 million remains in the trust account
Combined company to operate as Everli Global Holdings Inc. and trade on Nasdaq as EVRL and EVRLW once the deal closes
Citius Oncology received a Nasdaq notice on October 19, 2026 granting it until April 19, 2027 to evidence compliance with the $1.00 per share minimum bid price rule for continued Nasdaq Capital Market listing. The company's stock will keep trading under the symbol CTOR for now, but if it does not regain compliance by that date, Nasdaq will notify it that the stock is subject to delisting, and the company may appeal to a hearings panel.
Nasdaq extension runs through April 19, 2027 for compliance with the $1.00 per share bid price requirement.
Compliance requires a closing bid price of $1.00 or more for at least ten consecutive business days before April 19, 2027.
The company says it is evaluating options for regaining compliance and cannot assure it will do so.
The extension has no immediate effect on the CTOR listing on The Nasdaq Capital Market.
Polar Power, Inc. reported that it believes it has regained compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement, based on a series of convertible note, preferred stock, warrant and equity line transactions. The company estimates pro forma stockholders' equity of approximately $2.9 million, but the figures are preliminary and unaudited, and Nasdaq will keep monitoring compliance, so the company may still face delisting if it does not show compliance at its next periodic report.
Nasdaq deficiency letter dated May 1, 2026 cited the $2,500,000 minimum stockholders' equity rule; extension granted June 29, 2026
Company estimates preliminary pro forma stockholders' equity of approximately $2.9 million as of the filing date
Nasdaq will monitor compliance; the company may be subject to delisting if it does not evidence compliance at its next periodic report
Compliance must be demonstrated in a public report on or before October 28, 2026
Shore Bancshares furnished an investor presentation with third-quarter 2026 results showing net income of $16.8 million, or $0.50 per diluted share, down from $18.9 million, or $0.56 per share, in the second quarter. Net interest income rose 4.2% to $55.1 million and net interest margin widened to 3.78%, but a $5.3 million provision for credit losses, up from $0.9 million, and lower noninterest income reduced earnings.
Net income $16.8 million, or $0.50 per diluted share, versus $18.9 million, or $0.56 per share, in Q2 2026.
Net interest income $55.1 million, up 4.2%; net interest margin 3.78%, up from 3.70% in Q2 2026.
Provision for credit losses $5.3 million, versus $0.9 million in Q2 2026; total nonperforming assets $81.8 million at September 30, 2026.
Noninterest income $7.7 million, down from $8.8 million in Q2 2026.
Oak Valley Bancorp reported unaudited third-quarter 2026 net income of $6.45 million, or $0.77 per diluted share, up from $5.11 million in the second quarter but down from $6.69 million, or $0.81 per share, a year earlier. For the nine months ended September 30, 2026, net income was $16.87 million, or $2.02 per diluted share, versus $17.58 million, or $2.12 per share, in the same period of 2025, so results remain below last year's pace.
Q3 2026 net income $6.45 million, $0.77 diluted EPS, versus $5.11 million and $0.61 in Q2 2026 and $6.69 million and $0.81 in Q3 2025
Net interest margin rose to 4.24% in Q3 2026 from 4.15% in Q2 2026 and 4.16% in Q3 2025
Non-interest expense was $13.42 million in Q3 2026, down from $14.16 million in Q2 2026 but up from $12.70 million a year earlier
Total assets were $1.98 billion at September 30, 2026, down $25.4 million from June 30, 2026
SB Financial Group reported third quarter 2026 results in a news release dated October 22, 2026, furnished under Item 2.02 of this 8-K. Net income was $3.9 million, or $0.63 per diluted share, compared with $4.0 million, or $0.64, a year earlier, while operating revenue rose 9.0% to $18.1 million, but noninterest expense climbed 14.4%, which weighed on profit.
Q3 2026 GAAP net income was $3,946 thousand, down 2.5% from the prior-year quarter; diluted EPS was $0.63 versus $0.64.
Operating revenue was $18.1 million, up 9.0% year over year; net interest income rose 8.8% to $13.4 million.
Noninterest expense rose 14.4% to $13.2 million; the efficiency ratio was 72.46%, compared with 69.00% a year earlier.
Nine-month net income was $12.7 million, up 26.7%, and diluted EPS was $2.04, up 30.8% from $1.56.
T3 Defense Inc. said it believes it has regained compliance with Nasdaq's $10 million minimum stockholders' equity requirement, after holders exercised about 96% of its outstanding warrants as of September 30, 2026. The company has asked Nasdaq to confirm the resolution, but Nasdaq has not done so, and the company may face delisting if its next periodic report does not show compliance.
Nasdaq notice dated August 20, 2026 cited the $10,000,000 minimum stockholders' equity requirement under Listing Rule 5450(b)(1)(A).
Warrant liability rose from about $24.5 million at December 31, 2025 to about $124.4 million at June 30, 2026, producing a stockholders' deficit of about $19.7 million at that date.
As of September 30, 2026, warrant holders had exercised about 96% of outstanding warrants; pro forma stockholders' equity was about $99.9 million.
Nasdaq has not confirmed compliance; the next test is the Form 10-Q for the quarter ending September 30, 2026.
Bolt Biotherapeutics acquired Prana Therapies through a stock-for-stock reverse merger and, concurrently, agreed to a $120 million upfront private placement of Series D preferred stock. After the financing, pre-transaction Bolt holders are expected to own about 6.9% of common stock, Prana holders about 51.7%, and private placement investors about 41.4%, so existing Bolt shareholders face substantial dilution and a major change in ownership.
Bolt issued 430,746 shares of common stock and 16,360.929 shares of Series D preferred stock to Prana stockholders; each preferred share converts into 1,000 common shares.
The private placement covers 13,995.311 Series D preferred shares for $120 million in upfront gross proceeds, with warrants for up to an additional $60 million upon exercise.
Conversion of the Series D preferred stock requires Bolt stockholder approval, and the private placement is expected to close on October 26, 2026.
The company expects the financing to fund operations into 2028; lead program PRA-216 has Phase 2 patient data expected from the second quarter through the fourth quarter of 2027.
BV Financial, Inc. reported net income of $3.4 million, or $0.42 per diluted share, for the quarter ended September 30, 2026, compared with $3.7 million, or $0.41 per diluted share, a year earlier. Net interest income fell to $9.1 million from $9.4 million, while the share count reduction from buybacks helped per-share results. For shareholders, quarterly profit declined even as per-share earnings rose.
Q3 2026 net income was $3.4 million versus $3.7 million in Q3 2025; diluted EPS was $0.42 versus $0.41.
Nine-month net income was $8.0 million ($0.97 per diluted share) versus $8.7 million ($0.88) a year earlier.
Net interest income was $9.1 million for the quarter, down from $9.4 million, and total assets were $877.9 million at September 30, 2026.
The company repurchased 163,540 shares in the quarter at an average price of $21.16.
Eikon Therapeutics presented updated and initial clinical data from its PARP1 and WRN helicase programs at the 2026 ESMO Congress on October 23, 2026, and issued a press release on the results. The filing reports objective response rates alongside frequent Grade 3 or higher adverse events, and it contains no financial results, so the effect on shareholders is mixed and depends on later development steps.
EIK1003 Cohort 1C with weekly paclitaxel: objective response rate 26.4% (14/53); Grade 3 or higher adverse events in 80.3% (49/61) of participants
EIK1003 monotherapy Cohort 1A: objective response rate 14.3% (7/49) among efficacy-evaluable participants, with data cutoff October 1, 2026
EIK1004 monotherapy: objective response rate 12.1% (7/58); Grade 3 or higher adverse events in 17.6% (12/68) of participants
Further EIK1003 Cohort 1D and EIK1004 docetaxel combination results are expected in the second half of 2027
Aardvark Therapeutics reported exploratory efficacy and safety data from its previously terminated Phase 3 HERO trial and open-label extension, which the company says are directionally consistent with continued development of ARD-101 for Prader-Willi syndrome. The company states the partial data are not sufficient to draw definitive conclusions, the HERO trial was stopped early, and the FDA has lifted the clinical hold, so the company plans to request an FDA meeting on a new Phase 3 design.
HERO trial was terminated early with 67 of 90 planned participants randomized; all efficacy data are considered exploratory
OLE participants who switched from placebo to ARD-101 had an observed average 6-point reduction in HQ-CT score
One Grade 4 cardiac serious adverse event occurred at 800 mg twice daily with pitolisant, which the FDA concurred is related to a drug-drug interaction
FDA lifted the clinical hold on October 22, 2026; the company expects to resume PWS clinical activities in 2027
Rithm Capital reported third-quarter 2026 results for the period ended September 30, 2026. GAAP net income attributable to common stockholders rose to $217.1 million, or $0.38 per diluted share, from $20.2 million, or $0.04, in the second quarter, while total revenues increased to $1,756.4 million from $1,282.3 million. Earnings available for distribution, the company's non-GAAP measure, fell to $315.3 million, or $0.55 per diluted share, from $338.9 million, or $0.60, and the quarterly common dividend was unchanged at $0.25 per share.
GAAP net income attributable to common stockholders was $217.1 million, or $0.38 per diluted share, versus $20.2 million, or $0.04, in Q2 2026.
Earnings available for distribution were $315.3 million, or $0.55 per diluted share, versus $338.9 million, or $0.60, in Q2 2026.
Total revenues were $1,756.4 million, up from $1,282.3 million in Q2 2026.
The common dividend was $0.25 per share, unchanged from Q2 2026, and book value per common share was $12.51.
SLB reported third-quarter 2026 revenue of $9.45 billion, up 5% sequentially and 6% year on year, with growth led by the Middle East recovery and North America. GAAP diluted EPS was $0.49, down 6% sequentially and 2% year on year, so higher sales did not translate into higher year-on-year profit. The board also approved a quarterly dividend of $0.295 per share.
Revenue of $9.45 billion rose 5% sequentially and 6% year on year; ChampionX contributed $956 million.
GAAP diluted EPS was $0.49; EPS excluding charges and credits was $0.64, up 16% sequentially but down 7% year on year.
Free cash flow was $828 million and share repurchases totaled $656 million in the quarter.
Board approved a quarterly cash dividend of $0.295 per share, payable January 7, 2027, to holders of record on December 2, 2026.
Booz Allen Hamilton reported fiscal second-quarter 2027 results for the period ended September 30, 2026, with revenue of $2.8 billion, down 3.9% year over year, while net income rose 3.4% to $181 million. The company raised its fiscal 2027 Adjusted Diluted EPS guidance to $6.50 to $6.70 from $6.00 to $6.35, but revenue guidance midpoint was unchanged and the revenue growth range was narrowed.
Q2 revenue of $2.8 billion, down 3.9%; net income of $181 million, up 3.4%
Adjusted Diluted EPS of $1.76, up 18.1%; GAAP diluted EPS of $1.50, up 5.6%
Fiscal 2027 Adjusted Diluted EPS guidance raised to $6.50 to $6.70 from $6.00 to $6.35
Fiscal 2027 revenue guidance of $11.3 billion to $11.6 billion, versus $11.2 billion to $11.7 billion previously
Tango Therapeutics reported updated Phase 1/2 data for vopimetostat combined with Revolution Medicines' RAS(ON) inhibitors, with an 82% objective response rate in 22 efficacy-evaluable pancreatic cancer patients as of an August 20, 2026 data cutoff. The company also approved a strategic reprioritization on October 22, 2026, which includes reducing its workforce by approximately 14%, mostly in research, and deprioritizing novel target discovery. For shareholders, the data support a planned Phase 3 study, while the restructuring and the dose level 2 safety results add uncertainty.
Pancreatic cohort: 82% objective response rate (18 of 22), median PFS not yet reached, 9-month PFS rate of 88%, as of August 20, 2026
Dose level 2 (250 mg vopimetostat) was not well tolerated, with 3 dose-limiting toxicities in 2 of 4 safety-evaluable patients
Planned global randomized Phase 3 in front-line MTAP-deleted pancreatic cancer expected to start in the first half of 2027; NSCLC monotherapy data now expected in January 2027
Board approved reprioritization on October 22, 2026; approximately 14% workforce reduction, mostly in the research group
FTAI Infrastructure's Jefferson Terminal unit announced plans for a private offering of up to $270 million of notes, a preliminary amount subject to market conditions, to finance its acquisition of DRUbit LLC for an enterprise value of $255 million and pay related fees. Jefferson reported a net loss of approximately $52.2 million for the six months ended June 30, 2026, and expects the acquisition to more than double its annual Adjusted EBITDA to about $100 million, though the filing gives no assurance the financing will be completed.
Notes offering of up to $270 million, preliminary and subject to change, to be offered to qualified institutional buyers and non-U.S. persons
Acquisition of DRUbit LLC from an affiliate of US Development Group LLC at an enterprise value of $255 million, announced in a September 28, 2026 8-K
Jefferson reported a six-month net loss of approximately $52.2 million and Adjusted EBITDA of approximately $19.2 million
Jefferson targets 2027 Adjusted EBITDA of approximately $138 million and total debt of approximately $1,214 million on a pro forma basis
MarketAxess reported third-quarter 2026 revenue of $210.4 million, up 1% from a year earlier, while diluted EPS fell to $1.53 from $1.84 as expenses rose 10% and included $13.1 million of merger-related costs. The company withdrew its 2026 annual guidance and medium-term targets, and it declared a $0.78 quarterly dividend, both tied to its pending merger with Intercontinental Exchange, under which shareholders would receive $167.00 in cash per share.
Q3 2026 revenue $210.4 million, up 1%; net income $54.0 million, down 21%; diluted EPS $1.53 vs. $1.84 a year earlier
EPS excluding notable items was $1.86, up 1% from $1.84; operating margin was 35.4%, down 560 basis points
2026 annual guidance and medium-term financial targets withdrawn; earnings conference calls and monthly volume releases suspended
Merger with ICE at $167.00 cash per share; DOJ and FTC granted early termination of the HSR waiting period on October 21, 2026; stockholder approval and other conditions remain
Flagstar Bank reported third quarter 2026 net income attributable to common stockholders of $3 million, or $0.01 per diluted share, down from $26 million, or $0.06, in the second quarter but up from a $45 million loss in the third quarter of 2025. The quarter included a $22 million income tax benefit from a federal tax audit settlement, while the provision for credit losses rose $58 million to $76 million, and management said full achievement of its long-term strategic objectives has shifted to 2028 from 2027.
Total revenues rose 3% to $530 million from $516 million in the second quarter, and net interest income rose 5% to $460 million
Provision for credit losses increased $58 million to $76 million, mainly reflecting net charge-offs of $74 million
A $22 million income tax benefit from the settlement of a 2019-2021 federal tax audit helped results
Management moved the full realization of its long-term strategic objectives to 2028 from 2027, citing a higher-for-longer interest rate environment
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.